CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk NMIBC Overview Company: CG Oncology, Inc. Indication: Intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC) Drug: Cretostimogene Trial Phase: Phase 3 NCT ID: NCT06111235 Trial Details On February 27, 2024, CG Oncology announced the commencement of their Phase 3 PIVOT-006 clinical trial. This pivot..
Tonix Pharmaceuticals Reveals Promising Pharmacokinetics of Cyclobenzaprine for Fibromyalgia in Japan and China Company: Tonix Pharmaceuticals, Inc. Indication: Fibromyalgia Drug: Tonmya™ (TNX-102 SL, cyclobenzaprine HCl sublingual tablets) Trial Phase: Phase 3 NCT ID: N/A Overview Tonix Pharmaceuticals, Inc., a pioneering biopharmaceutical company, disclosed favorable outcomes from its pharmaco..
Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension Overview Company: Third Pole Therapeutics Indication: Pulmonary hypertension associated with Interstitial Lung Disease (ILD) Drug: eNOfit™ (Inhaled Nitric Oxide Delivery System) Trial Phase: N/A NCT ID: Not available Early Feasibility Study (EFS) Success Third Pole Therapeutics, a forefr..
Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines Company: Baseimmune Indication: - African swine fever - Coronavirus - Malaria Drug: AI-designed cross-protective vaccine candidates Trial Phase: N/A NCT ID: N/A Overview Baseimmune is a biotechnological firm committed to leading vaccine innovation using a proprietary artifici..
PolarityTE Commences Phase III Trial for SkinTE in Diabetic Foot Ulcers Overview Company: PolarityTE Indication: Diabetic foot ulcers Drug: SkinTE Trial Phase: Phase 3 NCT ID: Not provided PolarityTE has initiated the first subject screening for their Phase III pivotal study, entitled 'COVER DFUS II', which investigates the use of their novel product SkinTE for the treatment of Wagner grade 1 di..
Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a..
Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Overview Kura Oncology, Inc., a company leading the way in precision medicine for cancer, has begun a promising new clinical trial for Acute Myeloid Leukemia (AML) treatment. Clinical Trial Details Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemi..
